Skip to main content
SpringerLink
Log in

Invasive breast cancer and ductal carcinoma in situ in young women

  • Chapter
Management of Rare Adult Tumours

  • 1015 Accesses

Abstract

Despite continuous diagnostic and therapeutic improvements breast cancer remains a substantial clinical problem. In 2006, nearly 300,000 women were diagnosed in the United States, and more than 40,000 patients died of their disease [46].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aebi S, De Ridder M, Vlastos G et al. (2006) Young age is a poor prognostic factor in women with stage I breast cancer. Eur J Cancer (Suppl 4): 121

    Google Scholar 

  2. Aebi S, Gelber S, Castiglione-Gertsch M et al. (2000) Is chemotherapy alone adequate for young women with estrogen-receptor-positive breast cancer? Lancet 355: 1869–74

    Article  CAS  PubMed  Google Scholar 

  3. Aebi S (2005) Special issues related to the adjuvant therapy in very young women. Breast 14: 594–9

    Article  PubMed  Google Scholar 

  4. Albain KS, Allred DC, Clark GM (1994) Breast cancer outcome and predictors of outcome: are there age differentials? JNatl Cancer Inst Monogr 35–42

    Google Scholar 

  5. Bartelink H, Horiot JC, Poortmans P et al. (2001) European Organization for Research and Treatment of Cancer Radiotherapy and Breast Cancer Groups. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345: 1378–87

    Article  CAS  PubMed  Google Scholar 

  6. Bartelink H, Horiot JC, Poortmans P et al. (2007) Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 25: 3259–65

    Article  PubMed  Google Scholar 

  7. Bijker N, Peterse JL, Duchateau L et al. (2001) Risk factors for recurrence and metastasis after breast conserving therapy for ductal carcinoma in situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 19: 2263–71

    CAS  PubMed  Google Scholar 

  8. Bijker N, Meijnen P, Bogaerts J, Peterse JL (2006) Breast-conserving treatment with or without radiotherapy for ductal carcinoma in situ (DCIS): ten-year results of European Organisation for Research and Treatment of Cancer (EORTC) randomized phase III trial 10853. Eur J Cancer 4 Suppl: 108

    Google Scholar 

  9. Braun S, Vogl FD, Naume B et al. (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353: 793–802

    Article  CAS  PubMed  Google Scholar 

  10. Brinton LA, Sherman ME, Carreon JD, Anderson WF (2008) Recent Trends in Breast Cancer Among Younger Women in the United States. JNatl Cancer Inst 100: 1643–8

    Article  Google Scholar 

  11. Castiglione-Gertsch M, O’Neill A, Price KN et al. (2003) Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph nodenegative breast cancer: a randomized trial. J Natl Cancer Inst 95: 1833–46

    PubMed  Google Scholar 

  12. Colleoni M, Rotmensz N, Robertson C et al. (2002) Very young women (< 35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 13: 273–9

    Article  CAS  PubMed  Google Scholar 

  13. Colleoni M, Rotmensz N, Peruzzotti G et al. (2006) Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol 17: 1497–503

    Article  CAS  PubMed  Google Scholar 

  14. Coulombe G, Tyldesley S, Speers C et al. (2002) Is mastectomy superior to breastconserving treatment for young women? Int J Radiat Oncol Biol Phys 67: 1282–90

    Google Scholar 

  15. Cutuli B, Cohen-Solal-le Nir C, de Lafontan B et al. (2002) Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers’ experience. Int J Radiat Oncol Biol Phys 53: 868–79

    Article  PubMed  Google Scholar 

  16. Cuzick J, Ambroisine L, Davidson N et al. (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369: 1711–23

    Article  CAS  PubMed  Google Scholar 

  17. Davidson NE, O’Neill AM, Vukov AM et al. (2005) Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 23: 5973–82

    Article  CAS  PubMed  Google Scholar 

  18. Dite GS, Jenkins MA, Southey MC et al. (2003) Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst 95: 448–57

    Article  CAS  PubMed  Google Scholar 

  19. Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–717

    Article  Google Scholar 

  20. Elkum N, Dermime S, Ajarim D et al. (2007) Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: The Saudi Arabia experience. BMC Cancer 7: 222

    Article  PubMed  Google Scholar 

  21. Fodor J, Polgar C, Major T, Nemeth G (2003) Locoregional failure 15 years after mastectomy in women with one to three positive axillary nodes with or without irradiation: the significance of tumor size. Strahlenther Onkol 179: 197–202

    Article  PubMed  Google Scholar 

  22. Freedman GM, Hanlon AL, Fowble BL et al. (2002) Recursive partitioning identifies patients at high and low risk for ipsilateral tumor recurrence after breastconserving surgery and radiation. J Clin Oncol 20: 4015–21

    Article  CAS  PubMed  Google Scholar 

  23. Garg AK, Oh JL, Oswald MJ et al. (2007) Effect of postmastectomy radiotherapy in patients < 35 years old with stage II-III breast cancer tretated with doxorubicin-based neoadjuvant chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys 69: 1478–83

    Article  CAS  PubMed  Google Scholar 

  24. Goldhirsch A, Gelber RD, Yothers G et al. (2001) Adjuvant therapy for very young women with breast cancer: Need for tailored treatments. J Natl Cancer Inst Monogr 30: 44–51

    PubMed  Google Scholar 

  25. Goldhirsch A, Glick JH, Gelber RD et al. (2001) Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Clin Oncol 19: 3817–27

    CAS  PubMed  Google Scholar 

  26. Goldstein NS, Vicini FA, Kestin LL, Thomas M (2000) Differences in the pathologic features of ductal carcinoma in situ of the breast based on patient age. Cancer 88: 2553–60

    Article  CAS  PubMed  Google Scholar 

  27. Gruber G, Cole BF, Castiglione-Gertsch M et al. (2008) Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Ann Oncol 19: 1393–401

    Article  CAS  PubMed  Google Scholar 

  28. Hooning MJ, Aleman BMP, Hauptmann M et al. (2008) Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol Oct 14th [epub ahead of print]

    Google Scholar 

  29. Ismail-Khan R, Minton S, Cox C et al. (2008) Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: A randomized trial using the GnRH agonist (triptorelin) during chemotherapy. ASCO Proceedings I, Abstr. 524; p12s

    Google Scholar 

  30. Jakesz R, Hausmaninger H, Kubista E et al. (2002) Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer — Austrian Breast and Colorectal Cancer Study Group trial 5. J Clin Oncol 20: 4621–27

    Article  CAS  PubMed  Google Scholar 

  31. Julian TB, Land SR, Wang Y et al. (2008) Is boost therapy necessary in the treatment of DCIS? ASCO Proceedings I, Abstr. 537; p15s

    Google Scholar 

  32. Karlsson P, Cole BF, Price KN et al. (2007) The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. J Clin Oncol 25: 2019–26

    Article  PubMed  Google Scholar 

  33. Kaufmann M, Jonat W, Blamey R et al. (2003) Survival analyses from the ZEBRA study. Goserelin (Zoladex®) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39: 1711–7

    Article  CAS  PubMed  Google Scholar 

  34. Kollias J, Elston CW, Ellis IO et al. (1997) Early-onset breast cancer — histopathological and prognostic considerations. Br J Cancer 75: 1318–23

    Article  CAS  PubMed  Google Scholar 

  35. Kroman N, Jensen M-B, Wohlfahrt J et al. (2000) Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 320: 474–9

    Article  CAS  PubMed  Google Scholar 

  36. Kroman N, Holtveg H, Wohlfahrt J et al. (2004) Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 100: 688–93

    Article  PubMed  Google Scholar 

  37. Omlin A, Amichetti M, Azria D et al. (2006) Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol 7: 652–6

    Article  PubMed  Google Scholar 

  38. Paik S, Tang G, Shak S et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24: 3726–34

    Article  CAS  PubMed  Google Scholar 

  39. Parulekar WR, Day AG, Ottaway JA et al. (2005) Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study — NCIC CTG MA.5. J Clin Oncol 23: 6002–8

    Article  PubMed  Google Scholar 

  40. Petrek JA, Naughton MJ, Case LD et al. (2006) Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24: 1045–51

    Article  PubMed  Google Scholar 

  41. Pierce LJ, Griffith KA, Buys S et al. (2008) Outcomes following breast conservation versus mastectomy in BRCA 1/2 carriers with early-stage breast cancer. ASCO Proceedings I, Abstr. 536; p15s

    Google Scholar 

  42. Rapiti E, Fioretta G, Verkooijen HM et al. (2005) Survival of young and older breast cancer patients in Geneva from 1990 to 2001. Eur J Cancer 41: 1446–52

    Article  PubMed  Google Scholar 

  43. Recchia F, Saggio G, Amiconi G et al. (2006) Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 106: 514–23

    Article  CAS  PubMed  Google Scholar 

  44. Rodrigues NA, Dillon D, Carter D et al. (2003) Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women. Cancer 97: 1393–403

    Article  PubMed  Google Scholar 

  45. Schaapveld M, Visser O, Louwman WJ et al. (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contra-lateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110: 189–97

    Article  CAS  PubMed  Google Scholar 

  46. Smigal C, Jemal A, Ward E et al. (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56: 168–83

    Article  PubMed  Google Scholar 

  47. Swain SM, Land SR, Ritter MW et al. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat. 2008 Feb 27 [Epub ahead of print]

    Google Scholar 

  48. Taghian A, Jeong JH, Mamounas E et al. (2004) Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol 22: 4247–54

    Article  PubMed  Google Scholar 

  49. Tai P, Cserni G, Van de Steene J et al. (2005) Modelling the effect of age in T1-2 breast cancer using the SEER database. BMC Cancer 5: 130

    Article  PubMed  Google Scholar 

  50. Van de Vijver MJ, He YD, van’t Veer LJ et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999–2009

    Article  PubMed  Google Scholar 

  51. Viani GA, Stefano EJ, Afonso SL et al. (2007) Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials. Radiation Oncology 2: 28

    Article  PubMed  Google Scholar 

  52. Vicini FA, Recht A (2002) Age at diagnosis and outcome for women with ductal carcinoma-in-situ of the breast: a critical review of the literature. J Clin Oncol 20: 2736–44

    Article  PubMed  Google Scholar 

  53. Voogd AC, Nielsen M, Peterse JL et al. (2001) Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 19: 1688–97

    CAS  PubMed  Google Scholar 

  54. Vrieling C, Collette L, Fourquet A et al. (2003) Can patient-, treatment-and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur J Cancer 39: 932–44

    Article  CAS  PubMed  Google Scholar 

  55. Zhou P, Recht A (2004) Young age and outcome for women with early-stage invasive breast carcinoma. Cancer 101: 1264–74

    Article  PubMed  Google Scholar 

Download references

Authors
  1. G. Gruber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Aebi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hôpital Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000, Créteil Cedex, France

    Yazid Belkacémi MD PhD (Professor Radiation Oncology, Deputy Head of the Department of Radiation Oncology) (Professor Radiation Oncology, Deputy Head of the Department of Radiation Oncology)

  2. Centre hospitalier universitaire Vaudoir, Rue du Bugnon, CH-1011, Lausanne, Switzerland

    René-Olivier Mirimanoff MD (Professeur Radiation Oncology, Head of the Department of Radiation Oncology) & Mahmut Ozsahin MD PhD (Associate Professor in the Department of Radiation Oncology) (Professeur Radiation Oncology, Head of the Department of Radiation Oncology) &  (Associate Professor in the Department of Radiation Oncology)

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Gruber, G., Aebi, S. (2009). Invasive breast cancer and ductal carcinoma in situ in young women. In: Belkacémi, Y., Mirimanoff, RO., Ozsahin, M. (eds) Management of Rare Adult Tumours. Springer, Paris. https://doi.org/10.1007/978-2-287-92246-6_36

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-92246-6_36

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-92245-9

  • Online ISBN: 978-2-287-92246-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation